An investigation on behalf of investors of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) shares over potential securities laws violations by Tetraphase Pharmaceuticals and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) concerning whether a series of statements by Tetraphase Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Watertown, MA based Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. Tetraphase Pharmaceuticals Inc reported that its annual Total Revenue declined from $11.69 million in 2015 to $5.14 million in 2016 and that its Net Loss declined from $83.19 million in 2015 to $77.48 million in 2016.

On February 13, 2018, T Tetraphase Pharmaceuticals Inc announced that its IGNITE3 clinical trial did not achieve its co-primary endpoints of responder rate at the end of treatment and test-of-cure visit. The price of Tetraphase stock fell significantly following the announcement.

Shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) declined on February 20, 2018, to $2.07 per share.